|Articles|July 1, 2013

Waters Introduces Ion Mobility-Enhanced Research Mass Spectrometer

Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power.

Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power into a new suite of untargeted and targeted LC/MS/MS workflows. The system combines the power of Travelling Wave (T-Wave) Ion Mobility Separations with new data acquisition and informatics technologies, and collision cross section (CCS) measurements.

The mass spectrometer is the first MS system to elevate CCS alongside retention time and mass to charge ratio (m/z) as a robust, reliable identification parameter in library-based screening, according to a Waters press statement. The collision cross section of a molecule is an important distinguishing feature that is directly related to its chemical structure and three-dimensional conformation in the gas-phase. Like molecular mass, this additional orthogonal property of a molecule (through the use of high-efficiency T-wave ion mobility technology) gives scientists increased coverage and clarity for profiling mixtures or gaining additional measurements with which they can investigate chemical structures or better confirm a molecule's identity.

The system offers maximized time-of-flight (Tof) duty cycle and effective sensitivity, of up to 10x in MS/MS mode, for targeted discovery and quantitation. Improved LC/MS/MS efficiency includes a 40% improvement in the numbers of proteins identified from an E. coli sample and the identification of more than 2,000 proteins from a HeLa sample. A 2.5KHz solid-state laser combines with new software for improved spatial resolution (down to 15 microns) for cleaner mass spectral data and greater image throughput when performing experiments with MALDI imaging and T-wave ion mobility.


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.